Balaxi Pharmaceuticals Ltd

Stage 4 · Declining · week 19

As of 20 Nov 2026, Balaxi Pharmaceuticals is in Stage 4, the downtrend phase, now in week 19 (since 13 Jul 2026). It closed at ₹33.57, 12.1% below its 52-week high and above its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. More about the company

₹33.6
Close, 20 Nov 2026
-10.00% on the day
₹185 Cr · Micro cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dHealth Care Equipment & Supplies 0.0%-20.0 pts

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

RS rank

Edge

—

BALAXI is in a decline, 45% above its 200-day average. Declining stocks have lagged the market more than any other group; we wait for a base before looking again.

Its relative strength is 49 of 99, below the middle among NSE stocks over the past year. Health Care Equipment & Supplies ranks 45 of 106 industries by the strength of its stocks.

Is BALAXI early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S4 21w
S2 21w
S4 81w
S4 19w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 21w → S1 5w → S2 21w → S3 11w → S4 81w → S1 10w → S4 19w current
Total tracked: 169 weeks across 7 stage runs.

BALAXI among Health Care Equipment & Supplies4th of 11 by relative strength

All 11 →
Stocks in Health Care Equipment & Supplies ranked by relative strength, with stage and one-month change
#StockStageRS1M
1UNIVPHOTOStage 3 · wk 495+4.4%
2TARSONSStage 3 · wk 382+1.1%
3IKSStage 3 · wk 867+0.6%
4BALAXIStage 4 · wk 1949+59.1%
5POLYMEDStage 3 · wk 546+11.3%
6BOROSCIStage 4 · wk 645+5.3%
7LAXMIDENTLStage 4 · wk 1414+5.4%
8FISCHERStage 4 · wk 92−11.1%
vs 52W High
-12.1%
₹15.7 lo₹38.2 hi
12.1% below 52W high, failed near resistance
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 19
1w13w26w
Week 19, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
44.6%
200 DMA: ₹23.2 · sloping down
The stock is above its 200-day average while still in Stage 4. Stage analysis looks for it to hold there, and for the line to turn up, before reading a change of trend.
Rel Volume
4.39x
vs 50-day avg
Volume ran well above average on a down day. In Stage 4 that points to continued institutional selling.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+59.1%
3M
+41.1%
6M
+37.1%
YTD
+24.9%
1Y
-13.9%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Health Care Equipment & Supplies
↓ Peaking
Stage 2%
0.0%
20d Δ
-20.0pp
1M return
+6.1%
3M return
-0.8%
Industry Stage-2 % · last 20 days
Scan Membership
Not in any scan now.
Last appeared 26 Feb 2024
Recent Stage Timeline
2026-11-20S4
Wk 19 · Vol 4.39x
2026-11-19S4
Wk 18 · Vol 48.96x
2026-11-18S4
Wk 18 · Vol 49.15x
2026-11-17S4
Wk 18 · Vol 6.72x
2026-11-16S4
Wk 18 · Vol 0.45x
2026-11-13S4
Wk 18 · Vol 0.38x
2026-11-12S4
Wk 17 · Vol 1.92x
2026-11-11S4
Wk 17 · Vol 0.70x
2026-11-09S4
Wk 17 · Vol 0.47x
2026-11-06S4
Wk 17 · Vol 0.36x
2026-11-05S4
Wk 17 · Vol 0.50x
2026-11-04S4
Wk 16 · Vol 0.21x
Moving averages & range
50 DMA
₹22.9
200 DMA
₹23.2
52W High
₹38.2
52W Low
₹15.7
5D Low
₹22.1
Resistance levels (recent highs)
20d High
₹37.3
60d High
₹37.3
120d High
₹37.3
250d High
₹38.2
Next resistance
+11.1%
to 20d High
P/E (TTM)
52.1
Forward —
Earnings Growth (YoY)
-93.8%
Revenue +14.1%
Dividend Yield
0.00%
P/B 0.5

Balaxi Pharmaceuticals: quick answers

What stage is Balaxi Pharmaceuticals in?

As of 20 Nov 2026, Balaxi Pharmaceuticals (BALAXI) is in Stage 4, the downtrend phase. It entered Stage 4 on 13 Jul 2026 and is in week 19. What the four stages mean

Is Balaxi Pharmaceuticals in an uptrend?

No. Balaxi Pharmaceuticals is in a Stage 4 downtrend. It trades 44.6% above its 200-day average, which is falling.

How far is Balaxi Pharmaceuticals from its 52-week high?

Balaxi Pharmaceuticals closed at ₹33.57 on 20 Nov 2026, 12.1% below its 52-week high of ₹38.18. Its 52-week low is ₹15.67.

How has Balaxi Pharmaceuticals performed over the past year?

As of 20 Nov 2026, Balaxi Pharmaceuticals is down 13.9% over the past year and up 24.9% so far in 2026.

Which sector and industry is Balaxi Pharmaceuticals in?

Balaxi Pharmaceuticals is in the Health Care Equipment & Supplies industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care

About this companyHealth Care· Health Care Equipment & Supplies

Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.